Drugs@FDA document
CABAZITAXEL Review · NDA 207949 ORIG-1
Drugs@FDA document · ACCORD HLTHCARE · Jun 9, 2022
Key facts
| Drug name | CABAZITAXEL |
|---|---|
| Document type | Review |
| Application | NDA207949 |
| Submission | ORIG-1 |
| Company | ACCORD HLTHCARE |
| Document date | Jun 9, 2022 |
| FDA document | accessdata.fda.gov |
At a glance
- Officer/Employee List Document categories
- 10–99 Documents for this application
- None USP chapters cited in this application's documents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA documents
Drugs@FDA posts the letters, labels, reviews and other documents behind each drug application and supplement. Orca1 indexes every document's full text and flags complete response letters.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA application documents · Source date: